Tuesday
BioTech Webinars
Oct. 27th
1
11:00 am – 12:00 pm ET
Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions?
Category: Chronic conditions

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING

Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs
Eli Lilly and Company


Dan Cua, PhD
Vice President
IL-23 Pathway Area Leader for the Immunology Therapeutic Area
Janssen Biotech, Inc.


Dr. Mads Frederik Rasmussen
Corporate Project Vice President (CPVP) for GLP-1, CV and Outcomes
Novo Nordisk A/S


Marcella Ruddy
Vice President, Strategic Program Direction, Immunology and Inflammation
Regeneron

2
12:00 pm – 1:15 pm ET
Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions?
Category: Cancer, other rare conditions and vaccines

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING

Beth-Ann Coller, PhD
Executive Director, Global Clinical Development
Merck & Co., Inc

3
1:30 pm – 2:45 pm ET
Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments?
Category: Rare Genetic Disorders

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING

Pushkal Garg, MD
Chief Medical Officer
Alnylam
> More about the product (GIVLAARI)
> More about the product (ONPATTRO®)



Jonathan Sorof, M.D.
Senior Vice President, Head of Medical Affairs
Global Blood Therapeutics
